Table 3.
Variable | Genotypic frequencies | |||
---|---|---|---|---|
GG (N=266) | GC+CC (N=76) | OR (95% CI) | p value | |
Clinical Stage | ||||
Stage I/II | 176 (66.2%) | 48 (63.2%) | 1.00 | p=0.627 |
Stage III/IV | 90 (33.8%) | 28 (36.8%) | 1.141 (0.671-1.940) | |
Tumor size | ||||
≦ T2 | 180 (67.7%) | 48 (63.2%) | 1.00 | p=0.462 |
> T2 | 86 (32.3%) | 28 (36.8%) | 1.221 (0.717-2.079) | |
Lymph node metastasis | ||||
No | 256 (96.2%) | 74 (97.4%) | 1.00 | p=0.637 |
Yes | 10 (3.8%) | 2 (2.6%) | 0.692 (0.148-3.228) | |
Distant metastasis | ||||
No | 253 (95.1%) | 71 (93.4%) | 1.00 | p=0.560 |
Yes | 13 (4.9%) | 5 (6.6%) | 1.371 (0.473-3.974) | |
Vascular invasion | ||||
No | 222 (83.5%) | 60 (78.9%) | 1.00 | p=0.362 |
Yes | 44 (16.5%) | 16 (21.1%) | 1.345 (0.710-2.550) | |
Child-Pugh grade | ||||
A | 206 (77.4%) | 54 (71.1%) | 1.00 | p=0.250 |
B or C | 60 (22.6%) | 22 (28.9%) | 1.399 (0.789-2.481) | |
HBsAg | ||||
Negative | 163 (61.3%) | 37 (48.7%) | 1.00 | p=0.049* |
Positive | 103 (38.7%) | 39 (51.3%) | 1.668 (1.001-2.786) | |
Anti-HCV | ||||
Negative | 136 (51.1%) | 42 (55.3%) | 1.00 | p=0.525 |
Positive | 130 (48.9%) | 34 (44.7%) | 0.847 (0.507-1.413) | |
Liver cirrhosis | ||||
Negative | 53 (19.9%) | 15 (19.7%) | 1.00 | p=0.971 |
Positive | 213 (80.1%) | 61 (80.3%) | 1.012 (0.534-1.919) |
The ORs with analyzed by their 95% CIs were estimated by logistic regression models.
> T2: multiple tumor more than 5 cm or tumor involving a major branch of the portal or hepatic vein(s)
* p value < 0.05 as statistically significant.